Michael J Ferguson1, Steven D Rhodes1,2, Li Jiang1,2, Xiaohong Li1,2, Jin Yuan1,2, Xianlin Yang1,2, Shaobo Zhang3, Saeed T Vakili3, Paul Territo4, Gary Hutchins4, Feng-Chun Yang1,2,5, David A Ingram1,2, D Wade Clapp1,2,6, Shi Chen1,2. 1. Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana. 2. Herman B Wells Center for Pediatric Research, Indianapolis, Indiana. 3. Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 4. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana. 5. Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana. 6. Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract
PURPOSE: Plexiform neurofibromas (pNF) are pathognomonic nerve and soft tissue tumors of neurofibromatosis type I (NF1), which are highly resistant to conventional chemotherapy and associated with significant morbidity/mortality. Disruption of aberrant SCF/c-Kit signaling emanating from the pNF microenvironment induced the first ever objective therapeutic responses in a recent phase 2 trial. Sunitinib malate is a potent, highly selective RTK inhibitor with activity against c-Kit, PDGFR, and VEGFR, which have also been implicated in the pathogenesis of these lesions. Here, we evaluate the efficacy of sunitinib malate in a preclinical Krox20;Nf1(flox/-) pNF murine model. EXPERIMENTAL DESIGN: Proliferation, β-hexosaminidase release (degranulation), and Erk1/2 phosphorylation were assessed in sunitinib treated Nf1(+/-) mast cells and fibroblasts, respectively. Krox20;Nf1(flox/-) mice with established pNF were treated sunitinib or PBS-vehicle control for a duration of 12 weeks. pNF metabolic activity was monitored by serial [(18)F]DG-PET/CT imaging. RESULTS: Sunitinib suppressed multiple in vitro gain-in-functions of Nf1(+/-) mast cells and fibroblasts and attenuated Erk1/2 phosphorylation. Sunitinib treated Krox20;Nf1(flox/-) mice exhibited significant reductions in pNF size, tumor number, and FDG uptake compared to control mice. Histopathology revealed reduced tumor cellularity and infiltrating mast cells, markedly diminished collagen deposition, and increased cellular apoptosis in sunitinib treated pNF. CONCLUSIONS: Collectively, these results demonstrate the efficacy of sunitinib in reducing tumor burden in Krox20;Nf1(flox/-) mice. These preclinical findings demonstrate the utility of inhibiting multiple RTKs in pNF and provide insights into the design of future clinical trials.
PURPOSE: Plexiform neurofibromas (pNF) are pathognomonic nerve and soft tissue tumors of neurofibromatosis type I (NF1), which are highly resistant to conventional chemotherapy and associated with significant morbidity/mortality. Disruption of aberrant SCF/c-Kit signaling emanating from the pNF microenvironment induced the first ever objective therapeutic responses in a recent phase 2 trial. Sunitinib malate is a potent, highly selective RTK inhibitor with activity against c-Kit, PDGFR, and VEGFR, which have also been implicated in the pathogenesis of these lesions. Here, we evaluate the efficacy of sunitinib malate in a preclinical Krox20;Nf1(flox/-) pNF murine model. EXPERIMENTAL DESIGN: Proliferation, β-hexosaminidase release (degranulation), and Erk1/2 phosphorylation were assessed in sunitinib treated Nf1(+/-) mast cells and fibroblasts, respectively. Krox20;Nf1(flox/-) mice with established pNF were treated sunitinib or PBS-vehicle control for a duration of 12 weeks. pNF metabolic activity was monitored by serial [(18)F]DG-PET/CT imaging. RESULTS:Sunitinib suppressed multiple in vitro gain-in-functions of Nf1(+/-) mast cells and fibroblasts and attenuated Erk1/2 phosphorylation. Sunitinib treated Krox20;Nf1(flox/-) mice exhibited significant reductions in pNF size, tumor number, and FDG uptake compared to control mice. Histopathology revealed reduced tumor cellularity and infiltrating mast cells, markedly diminished collagen deposition, and increased cellular apoptosis in sunitinib treated pNF. CONCLUSIONS: Collectively, these results demonstrate the efficacy of sunitinib in reducing tumor burden in Krox20;Nf1(flox/-) mice. These preclinical findings demonstrate the utility of inhibiting multiple RTKs in pNF and provide insights into the design of future clinical trials.
Authors: Amy M Munchhof; Fang Li; Hilary A White; Laura E Mead; Theresa R Krier; Amy Fenoglio; Xiaohong Li; Jin Yuan; Feng-Chun Yang; David A Ingram Journal: Hum Mol Genet Date: 2006-04-28 Impact factor: 6.150
Authors: Fang Li; Amy M Munchhof; Hilary A White; Laura E Mead; Theresa R Krier; Amy Fenoglio; Shi Chen; Xiaohua Wu; Shanbao Cai; Feng-Chun Yang; David A Ingram Journal: Hum Mol Genet Date: 2006-04-27 Impact factor: 6.150
Authors: Feng-Chun Yang; Shi Chen; Travis Clegg; Xiaohong Li; Trent Morgan; Selina A Estwick; Jin Yuan; Waleed Khalaf; Sarah Burgin; Jeff Travers; Luis F Parada; David A Ingram; D Wade Clapp Journal: Hum Mol Genet Date: 2006-07-11 Impact factor: 6.150
Authors: D Babovic-Vuksanovic; K Ballman; V Michels; P McGrann; N Lindor; B King; J Camp; V Micic; N Babovic; X Carrero; R Spinner; B O'Neill Journal: Neurology Date: 2006-10-11 Impact factor: 9.910
Authors: Brigitte C Widemann; Wanda L Salzer; Robert J Arceci; Susan M Blaney; Elizabeth Fox; David End; Andrea Gillespie; Patricia Whitcomb; Joseph S Palumbo; Aaron Pitney; Nalini Jayaprakash; Peter Zannikos; Frank M Balis Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 44.544
Authors: George A Mashour; Pablo Hernáiz Driever; Melanie Hartmann; Stephanie N Drissel; Tingguo Zhang; Bianca Scharf; Ursula Felderhoff-Müser; Sadatoshi Sakuma; Reinhard E Friedrich; Robert L Martuza; Victor Felix Mautner; Andreas Kurtz Journal: Clin Cancer Res Date: 2004-09-01 Impact factor: 12.531
Authors: Feng-Chun Yang; David A Ingram; Shi Chen; Cynthia M Hingtgen; Nancy Ratner; Kelly R Monk; Travis Clegg; Hilary White; Laura Mead; Mary Jo Wenning; David A Williams; Reuben Kapur; Simon J Atkinson; D Wade Clapp Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Julie A Mund; SuJung Park; Abbi E Smith; Yongzheng He; Li Jiang; Eric Hawley; Michelle J Roberson; Dana K Mitchell; Mohannad Abu-Sultanah; Jin Yuan; Waylan K Bessler; George Sandusky; Shi Chen; Chi Zhang; Steven D Rhodes; D Wade Clapp Journal: J Biol Chem Date: 2020-05-29 Impact factor: 5.157
Authors: Michael J Fisher; Chie-Schin Shih; Steven D Rhodes; Amy E Armstrong; Pamela L Wolters; Eva Dombi; Chi Zhang; Steven P Angus; Gary L Johnson; Roger J Packer; Jeffrey C Allen; Nicole J Ullrich; Stewart Goldman; David H Gutmann; Scott R Plotkin; Tena Rosser; Kent A Robertson; Brigitte C Widemann; Abbi E Smith; Waylan K Bessler; Yongzheng He; Su-Jung Park; Julie A Mund; Li Jiang; Khadijeh Bijangi-Vishehsaraei; Coretta Thomas Robinson; Gary R Cutter; Bruce R Korf; Jaishri O Blakeley; D Wade Clapp Journal: Nat Med Date: 2021-01-13 Impact factor: 53.440
Authors: M Mauda-Havakuk; B Shofty; S Ben-Shachar; L Ben-Sira; S Constantini; F Bokstein Journal: AJNR Am J Neuroradiol Date: 2017-08-10 Impact factor: 3.825
Authors: Juan Mo; Corina Anastasaki; Zhiguo Chen; Tracey Shipman; Jason Papke; Kevin Yin; David H Gutmann; Lu Q Le Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808